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Objectives. The aim was to explore the current experience and practice of vascular surgeons in the United Kingdom and
Ireland regarding foam sclerotherapy for varicose veins.
Method. A postal questionnaire was sent to 609 members of the Vascular Society of Great Britain and Ireland.
Results. There were 281 responses (47%). Seventy surgeons (25%) used foam sclerotherapy. Most use it selectively; few
(29%) offer it to all patients. It was more likely to be used for recurrent varices (71%), in older patients (61%) and for
smaller non-saphenous varices (67%). The majority of surgeons (69%) used sodium tetradecyl sulphate and up to a
maximum of 10e12 ml of foam. The majority used ultrasound guidance (95%), leg elevation (69%) and direct pressure
over the saphenofemoral or saphenopopliteal junction during injection (63%). Eighty per cent used compression bandaging
after treatment, usually for 7 days (44%). Ninety percent advised compression stockings, usually Class II (64%) for 14
days (39%). Serious complications were few, but eleven surgeons had seen a deep vein thrombosis, two had seen a patient
with a stroke and one a transient ischaemic attack.
Conclusion. Foam sclerotherapy was used by a quarter of surgeons who replied to the survey. Aspects of technique varied
considerably and studies to determine optimal techniques are needed. Serious complications with the technique were rare.
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Surgery remains the standard treatment for symptom-
atic and complicated varicose veins.1 However, there
are a number of new endovenous techniques that are
under investigation. The use of foam sclerotherapy
as an alternative to surgery is gaining in popularity.
Although foam treatment was reported as long ago
as 1939 by Stuard McAusland2 the most widely
used method of foam production was described by
Tessari in 2001.3 It is therefore a new and evolving
technique. At a European consensus meeting in
20034 an attempt was made to harmonise opinion
and define principles of safe and effective practice.
A recent report of ischaemic stroke after foam sclero-
therapy in a patient with a patent foramen ovale5 has
focussed attention on the potential for embolic com-
plications. The aim of this survey was to explore the
current experience and practice of members of the
Vascular Society of Great Britain and Ireland with
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varicose veins.
Materials and Methods
A postal questionnaire was sent to 609 members of the
Vascular Society during May 2006. The questionnaire
sought information about their use of foam sclerother-
apy, the indications, the technique used including
post-treatment compression, and the complications
clinicians had seen. Not all questions were answered
by every respondent.
Results
A total of 281 completed questionnaires were returned
with a further 11 returned unopened giving a response
rate of 47%. Of those who replied, 70 surgeons (25%)
had used foam sclerotherapy in the treatment of var-
icose veins. Analysis was carried out on the results
of these 70 postal questionnaires. The majority of
those who replied had performed fewer than 100
foam treatments; only very few had performedrved.
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undertaken was 35 (range 1e2000).
Patient selection
Few surgeons (20 of 69 surgeons who responded,
29%) offered foam sclerotherapy to most patients
with varicose veins. However, only 18 of 68 (26%)
reserved it for those unfit for, or refusing surgery.
The majority recommended it selectively for patients
with recurrent varices (49 of 69, 71%), to older patients
(42 of 69, 61%) and to those with smaller non-
saphenous varices (47 of 70, 67%). Sixty-four percent
(43 of 67) used foam sclerotherapy to treat patients
with a venous leg ulcer. Twenty-three of 66 (35%)
tended to avoid foam in very obese patients, where
phlebitis can be a problem.
Sclerosant foam
The majority of surgeons (48 of 70, 69%) used sodium
tetradecyl sulphate (STD) as the sclerosant. Sixteen
percent of surgeons (12 of 70) used polidocanol and
the remaining ten (14%) made use of both agents.
All but one used the Tessari method of foam
production.
The most commonly used sclerosant concentration
for truncal varices was 3% for both STD (39) and
Polidocanol (10) although significant numbers used
1e2% solutions (10 and 7, respectively). Themaximum
volume of foam surgeons were happy to use in one
treatment session varied quite markedly (Fig. 1),
10 ml (14) and 12 ml (11) being themost common. There
was no correlation between the surgeon’s experience
with foam and the volume of foam used.
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Fig. 1. The maximum volume of foam surgeons usually
employed in one treatment session.Technique
The vast majority of surgeons (58 of 62, 94%) usually
cannulated the great saphenous vein (GSV) or small
saphenous vein (SSV) under ultrasound guidance.
Most (60 of 64, 94%) monitored the progress of foam
injected into the vein using ultrasound imaging
(Fig. 2). The leg was elevated before foam injection
by 69% (43 of 62) and foam was milked along the
vein using surface pressure by 68% (42 of 62). Sixty
three percent (39 of 62) routinely blocked the sapheno-
femoral or saphenopopliteal junction during foam
injection. The commonest technique employed was
to treat the main incompetent vein first, with a sepa-
rate session for treatment of any remaining smaller
varicosities: 62% (40 of 65 surgeons). Seventy-one per-
cent of surgeons (46 of 65) varied the concentration of
the foam used depending on target vein size.
Post-treatment compression
Most surgeons (55 of 69, 80%) employed compression
bandaging after foam treatment; the remainder used
graduated compression immediately. Most commonly
used were Peha-Haft (Hartmann, Germany) (10 re-
sponses), Crepe (8) and Panelast (Lohmann & Rausch,
Germany) (6) bandages. The duration of compression
was variable but usually 1 (7 responses), 5 (9) or 7 (24)
days. A few surgeons recommended patients stay in
bandages for as long as a month (Fig. 3a).
The vast majority (62 of 69, 90%) advised patients
to wear compression stockings after the first few
days of compression bandaging. These were usually
Class II compression stockings (39 of 61, 64%) or
Fig. 2. Foam sclerosant injected via Venflon into the GSV
under ultrasound control.
234 J. L. O’Hare and J. J. Earnshawthrombo-embolic deterrent stockings (17 of 61, 28%).
The recommended duration of compression varied,
but was usually 7(18 replies) or 14 (23) days. A few
suggested remaining in stockings for as long as 3
months (Fig. 3b).
Complications
Major complications were described infrequently. Six-
teen percent (11) of surgeons had seen at least one
episode of deep vein thrombosis (DVT). Twenty-one
percent (15) had witnessed a transient visual distur-
bance. Two surgeons (3%) had seen a stroke and one
(1%) a transient ischaemic attack (TIA). None had
seen a pulmonary embolus or permanent visual
disturbance.
The most commonly seen minor complication was
skin staining (43, 61% of surgeons). Skin necrosis or
ulceration was described by 17% (12). Three percent
(2) had seen an allergic reaction. Other complications
were recorded by 17% of surgeons and included phle-
bitis (5 surgeons), lumpiness (3), fainting (2), cough-
ing (1), skin blistering (1), reticular varices (1) and
recurrence (1).
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Fig. 3. The duration of (a) compression bandaging and (b)
stocking use advised after foam sclerotherapy.Eur J Vasc Endovasc Surg Vol 34, August 2007Discussion
When members of the Vascular Society of Great
Britain and Ireland were last questioned about their
use of sclerotherapy in 1998,6 its use for varicose veins
was decreasing and few surgeons (10 of 178) said
they would use it in the presence of proximal saphe-
nous incompetence. Liquid sclerotherapy in these
patients gave poor results although it remained popu-
lar for treating telangiectasia. The technique of foam
sclerotherapy, where liquid sclerosant is mixed with
air, has since gained in popularity and appears to
give better results than liquid sclerotherapy for
patients with GSV incompetence.7,8 Foam enables
accurate injection of sclerosant under ultrasound
guidance and has proved effective even in large vari-
ces.9 The increased volume of foam displaces more
blood, at a lower dose, thus making it potentially
more efficacious. A number of authors have published
encouraging results after foam sclerotherapy with up
to 3 years follow-up.10e18
There was a relatively low response rate to this
questionnaire. However, it may be that most of the
vascular surgeons currently employing foam sclero-
therapy responded. Non-responders may have been
those without enthusiasm. A minimum of 70 surgeons
use foam regularly. The widespread use of duplex
ultrasound imaging, leg elevation and post-treatment
compression were all in line with the recommenda-
tions of the 2003 European Consensus meeting.4 How-
ever, the large volumes of foam used by some surgeons
were concerning andwere significantly higher than the
6e8 ml per session recommended by the Consensus
group.
Three separate surgeons documented that they had
seen a patient develop a stroke or TIA. Although im-
possible to get an accurate incidence from a survey,
the study involved a total of 4536 patients treated
with foam suggesting a maximum incidence of around
one in 1500. Neurological complications were seen by
both experienced and inexperienced users. There are
two reported cases of stroke in the literature.5,19 Both
occurred in patients with a patent foramen ovale, but
in only one was there convincing evidence that foam
had been the cause (foam particles seen in the carotid
artery after the injection of 20 ml foam).5 The other
case followed the use of liquid polidocanol. Although
rare, this is a serious complication from an elective
procedure done often for moderate symptoms. A pro-
spective registry of significant complications from
foam sclerotherapy, with details of the technique
used in each case, would be a useful step towards
gathering evidence about how complications might
be avoided. The significance of major complications
235Vascular Society Survey of Foam Sclerotherapyin the context of treating patients with uncomplicated
varicose veins requires debate. Other reported compli-
cations in this survey were similar to those described
in the literature, although in the authors’ experience
a degree of phlebitis and lumpiness in the treated
vein is far more common than reported here.
The REACTIV trial20 demonstrated that both sur-
gery and sclerotherapy are cost-effective treatments
for varicose veins. There are a number of new and
evolving office treatments for varicose veins and
controlled trials comparing the different methods are
needed urgently.21,22
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